MDGL vs. NBIX: A Head-to-Head Stock Comparison

Updated on October 10, 2025

Here’s a clear look at MDGL and NBIX, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

Symbol	MDGL	NBIX
Company Name	Madrigal Pharmaceuticals, Inc.	Neurocrine Biosciences, Inc.
Country	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry	Biotechnology	Biotechnology
Market Capitalization	9.74 billion USD	13.79 billion USD
Exchange	NasdaqGS	NasdaqGS
Listing Date	February 6, 2007	May 23, 1996
Security Type	Common Stock	Common Stock

Historical Performance

This chart compares the performance of MDGL and NBIX by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

MDGL vs. NBIX: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	MDGL	NBIX
5-Day Price Return	-2.82%	1.71%
13-Week Price Return	41.60%	4.17%
26-Week Price Return	33.58%	35.19%
52-Week Price Return	103.39%	24.00%
Month-to-Date Return	-4.73%	-0.93%
Year-to-Date Return	41.60%	1.89%
10-Day Avg. Volume	0.28M	1.01M
3-Month Avg. Volume	0.36M	0.89M
3-Month Volatility	47.95%	28.10%
Beta	-1.04	0.28

Profitability

Return on Equity (TTM)

MDGL

-38.38%

Biotechnology Industry

Max: 97.92%
Q3: 11.99%
Median: -19.30%
Q1: -51.29%
Min: -132.03%

MDGL has a negative Return on Equity of -38.38%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

NBIX

13.22%

Biotechnology Industry

Max: 97.92%
Q3: 11.99%
Median: -19.30%
Q1: -51.29%
Min: -132.03%

In the upper quartile for the Biotechnology industry, NBIX’s Return on Equity of 13.22% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

MDGL vs. NBIX: A comparison of their Return on Equity (TTM) against the Biotechnology industry benchmark.

Net Profit Margin (TTM)

MDGL

-54.68%

Biotechnology Industry

Max: 73.34%
Q3: 18.98%
Median: -12.96%
Q1: -105.72%
Min: -259.82%

MDGL has a negative Net Profit Margin of -54.68%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

NBIX

13.88%

Biotechnology Industry

Max: 73.34%
Q3: 18.98%
Median: -12.96%
Q1: -105.72%
Min: -259.82%

NBIX’s Net Profit Margin of 13.88% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.

MDGL vs. NBIX: A comparison of their Net Profit Margin (TTM) against the Biotechnology industry benchmark.

Operating Profit Margin (TTM)

MDGL

-60.09%

Biotechnology Industry

Max: 78.85%
Q3: 21.90%
Median: -13.30%
Q1: -109.94%
Min: -278.10%

MDGL has a negative Operating Profit Margin of -60.09%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

NBIX

19.72%

Biotechnology Industry

Max: 78.85%
Q3: 21.90%
Median: -13.30%
Q1: -109.94%
Min: -278.10%

NBIX’s Operating Profit Margin of 19.72% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.

MDGL vs. NBIX: A comparison of their Operating Profit Margin (TTM) against the Biotechnology industry benchmark.

Profitability at a Glance

Symbol	MDGL	NBIX
Return on Equity (TTM)	-38.38%	13.22%
Return on Assets (TTM)	-27.32%	9.39%
Net Profit Margin (TTM)	-54.68%	13.88%
Operating Profit Margin (TTM)	-60.09%	19.72%
Gross Profit Margin (TTM)	96.28%	98.49%

Financial Strength

Current Ratio (MRQ)

MDGL

5.11

Biotechnology Industry

Max: 16.97
Q3: 8.39
Median: 4.11
Q1: 2.64
Min: 0.74

MDGL’s Current Ratio of 5.11 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

NBIX

3.20

Biotechnology Industry

Max: 16.97
Q3: 8.39
Median: 4.11
Q1: 2.64
Min: 0.74

NBIX’s Current Ratio of 3.20 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

MDGL vs. NBIX: A comparison of their Current Ratio (MRQ) against the Biotechnology industry benchmark.

Debt-to-Equity Ratio (MRQ)

MDGL

0.17

Biotechnology Industry

Max: 1.92
Q3: 0.79
Median: 0.12
Q1: 0.00
Min: 0.00

MDGL’s Debt-to-Equity Ratio of 0.17 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

NBIX

0.00

Biotechnology Industry

Max: 1.92
Q3: 0.79
Median: 0.12
Q1: 0.00
Min: 0.00

NBIX’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

MDGL vs. NBIX: A comparison of their Debt-to-Equity Ratio (MRQ) against the Biotechnology industry benchmark.

Interest Coverage Ratio (TTM)

MDGL

-163.11

Biotechnology Industry

Max: 72.37
Q3: 1.03
Median: -9.59
Q1: -65.05
Min: -163.11

MDGL has a negative Interest Coverage Ratio of -163.11. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

NBIX

6.75

Biotechnology Industry

Max: 72.37
Q3: 1.03
Median: -9.59
Q1: -65.05
Min: -163.11

NBIX’s Interest Coverage Ratio of 6.75 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

MDGL vs. NBIX: A comparison of their Interest Coverage Ratio (TTM) against the Biotechnology industry benchmark.

Financial Strength at a Glance

Symbol	MDGL	NBIX
Current Ratio (MRQ)	5.11	3.20
Quick Ratio (MRQ)	4.48	3.10
Debt-to-Equity Ratio (MRQ)	0.17	0.00
Interest Coverage Ratio (TTM)	-163.11	6.75

Growth

Revenue Growth

MDGL vs. NBIX: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

MDGL vs. NBIX: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

MDGL

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MDGL currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

NBIX

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

NBIX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

MDGL vs. NBIX: A comparison of their Dividend Yield (TTM) against the Biotechnology industry benchmark.

Dividend Payout Ratio (TTM)

MDGL

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MDGL has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

NBIX

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

NBIX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

MDGL vs. NBIX: A comparison of their Dividend Payout Ratio (TTM) against the Biotechnology industry benchmark.

Dividend at a Glance

Symbol	MDGL	NBIX
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

Price-to-Earnings Ratio (TTM)

MDGL

Biotechnology Industry

Max: 40.44
Q3: 39.37
Median: 22.12
Q1: 15.76
Min: 3.48

P/E Ratio data for MDGL is currently unavailable.

NBIX

39.63

Biotechnology Industry

Max: 40.44
Q3: 39.37
Median: 22.12
Q1: 15.76
Min: 3.48

A P/E Ratio of 39.63 places NBIX in the upper quartile for the Biotechnology industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.

MDGL vs. NBIX: A comparison of their Price-to-Earnings Ratio (TTM) against the Biotechnology industry benchmark.

Price-to-Sales Ratio (TTM)

MDGL

18.93

Biotechnology Industry

Max: 92.67
Q3: 41.36
Median: 8.45
Q1: 4.46
Min: 0.97

MDGL’s P/S Ratio of 18.93 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

NBIX

5.50

Biotechnology Industry

Max: 92.67
Q3: 41.36
Median: 8.45
Q1: 4.46
Min: 0.97

NBIX’s P/S Ratio of 5.50 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

MDGL vs. NBIX: A comparison of their Price-to-Sales Ratio (TTM) against the Biotechnology industry benchmark.

Price-to-Book Ratio (MRQ)

MDGL

9.65

Biotechnology Industry

Max: 22.72
Q3: 10.68
Median: 4.55
Q1: 2.44
Min: 0.59

MDGL’s P/B Ratio of 9.65 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

NBIX

4.62

Biotechnology Industry

Max: 22.72
Q3: 10.68
Median: 4.55
Q1: 2.44
Min: 0.59

NBIX’s P/B Ratio of 4.62 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

MDGL vs. NBIX: A comparison of their Price-to-Book Ratio (MRQ) against the Biotechnology industry benchmark.

Valuation at a Glance

Symbol	MDGL	NBIX
Price-to-Earnings Ratio (TTM)	--	39.63
Price-to-Sales Ratio (TTM)	18.93	5.50
Price-to-Book Ratio (MRQ)	9.65	4.62
Price-to-Free Cash Flow Ratio (TTM)	282.95	26.11